Communiqués Laboratorios Farmaceuticos Rovi, S.A. Wiener Boerse

Actions

ROVI

ES0157261019

Produits pharmaceutiques

Cours en clôture Wiener Boerse 01/10/2026			Varia. 5j.	Varia. 1 janv.
57,65 ^EUR	-3,11 %		-3,27 %	-8,93 %

23/07	Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026
23/07	Laboratorios Farmacéuticos Rovi, S.A. publie ses résultats pour le premier semestre clos le 30 juin 2026	CI

Communiqués

23/07	Laboratorios Farmaceuticos Rovi S A : First half 2026 results press release	PU
08/07	Laboratorios Farmaceuticos Rovi S A : ROVI and the Regional Government of Castilla-La Mancha promote a framework of collaboration to modernise healthcare services through technological innovation	PU
06/05	Laboratorios Farmaceuticos Rovi S A : First three months of 2026 results press release	PU
25/02	Laboratorios Farmaceuticos Rovi S A : 2025 results press release	PU
18/11	Laboratorios Farmaceuticos Rovi S A : ROVI releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development	PU
06/11	Laboratorios Farmaceuticos Rovi S A : First nine months of 2025 results press release	PU
21/10/25	Laboratorios Farmaceuticos Rovi S A : ROVI announces a collaboration with Roche for the manufacture of a new medicine in development	PU
29/09/25	Laboratorios Farmaceuticos Rovi S A : ROVI announces the acquisition of an injectable drug product manufacturing site in Phoenix, Arizona (USA)	PU
24/07/25	Laboratorios Farmaceuticos Rovi S A : First half 2025 results press release	PU
18/06/25	Laboratorios Farmaceuticos Rovi S A : ROVI held its 2025 General Shareholders’ Meeting	PU
08/05/25	Laboratorios Farmaceuticos Rovi S A : First three months 2025 results press release	PU
25/03/25	Laboratorios Farmaceuticos Rovi S A : 2025 Capital Markets Day presentation	PU
25/02/25	Laboratorios Farmaceuticos Rovi S A : 2024 results press release	PU
07/11/24	Laboratorios Farmaceuticos Rovi S A : ROVI achieved operating revenue of 564.6 million euros and increased its gross margin by 4.7 percentage points	PU
07/11/24	Laboratorios Farmaceuticos Rovi S A : First nine months 2024 results press release	PU
24/10/24	Laboratorios Farmaceuticos Rovi S A : ROVI completes the strategic review of its CDMO business	PU
31/07/24	Laboratorios Farmaceuticos Rovi S A : First half 2024 results press release	PU
11/07/24	Laboratorios Farmaceuticos Rovi S A : ROVI invests 60 million euros to expand the production capacity of its San Sebastián de los Reyes plant by 31.5%	PU
24/06/24	Laboratorios Farmaceuticos Rovi S A : ROVI forecasts potential Risperidone ISM® sales of between 200 and 300 million euros globally in upcoming years	PU
20/06/24	Laboratorios Farmaceuticos Rovi S A : ROVI completes its new Escúzar plant by including a sodium heparin production facility	PU
08/05/24	Laboratorios Farmaceuticos Rovi S A : First three months 2024 results press release	PU
25/04/24	Laboratorios Farmaceuticos Rovi S A : ROVI announces agreement to manufacture pre-filled syringes	PU
12/03/24	Laboratorios Farmaceuticos Rovi S A : ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies	PU
10/11/23	Laboratorios Farmaceuticos Rovi S A : First nine months 2023 results press release	PU
28/07/23	Laboratorios Farmaceuticos Rovi S A : ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®	PU